T-Rex Luxury Bags? Scientists Plan To Use Leather From Dinosaur DNA
Regarded as one of the most fearsome creatures on planet Earth millions of years ago, the 40-foot-long Tyrannosaurus rex (T-Rex) could soon be used to make a fashion statement. In a first-of-its-kind approach to luxury fashion, researchers and bioengineers in the UK are planning to use lab-grown leather from fossilised T-Rex remains to make purses, clutches and totes.
Known as the King of the Dinosaurs, T Rex lived 68 million years ago in North America and Asia. Now, using T-Rex collagen as a blueprint, the researchers are hoping to develop the first example of leather, created from an extinct species.
'We're unlocking the potential to engineer leather from prehistoric species, starting with the formidable T-Rex,' Che Connon, professor of tissue engineering at Newcastle University, said in a statement.
"The hard bit is making leather from cells, and we've done that. The upstream bit is using existing technologies, which is why we're confident we can do this so quickly.'
The joint venture between creative agency VML and biotech companies The Organoid Company and Lab-Grown Leather Ltd. is hoping to produce a luxury fashion item as its flagship commercial product by the end of 2025.
"The material is fully biodegradable while maintaining the durability and repairability of traditional leather, offering a sustainable, cruelty-free, and traceable alternative for future generations of consumers, who demand both innovation and environmental responsibility."
While the claims by scientists are audacious, some palaeontologists have called them out for being 'misleading'.
"We have NO preserved tyrannosaurid DNA (indeed, not Mesozoic dinosaur DNA sequences), so there are no T-Rex genes,' Thomas Holtz, Jr., a vertebrate palaeontologist at the University of Maryland, told LiveScience.
Notably, DNA starts to decompose and decay as soon as an animal dies. The oldest preserved DNA on record is about two million years old, while the T-Rex went extinct 66 million years ago.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
3 days ago
- NDTV
New Hope For Patients With Less Common Breast Cancer
Virginia, United States: A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15-20 percent of all breast cancer cases. HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. "Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart Bomb' This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Ms Tolaney. "Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much." Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Ms Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 Percent Risk Reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 percent compared to standard care. Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Ms Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission. "This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study
News18
3 days ago
- News18
Pankaj Tripathi On Fake AI Videos: 'I Am Not Scared...'
Last Updated: Pankaj Tripathi discussed the rise of fake AI videos, stressing meaningful tech use. He believes human emotions hold more value. Actor Pankaj Tripathi, who was recently seen in Criminal Justice 4, spoke honestly about the rise of fake AI-generated videos in a new interview. Pankaj shared what he feels about this growing issue. When asked about fake AI content spreading online, he said in Hindi to Zoom TV, 'I remember reading an article in my childhood about science: is it a boon or a curse? What is it? It is both. If it is used meaningfully, then it is an amazing thing. If it is used meaninglessly or without meaning, then it can be harmful. Any technology should have a meaningful use." He added, 'But if there is technology, then it will have both kinds of uses. The person has to be aware that what they are seeing is generated or real and original. How much you will see and how much you will dissect or understand it? You have to live your life and work too. I am not scared because no matter how much technology evolves, human emotions have a lot of value and that is not going to change." In simple words, Pankaj believes that while technology like AI can be useful, it can also be misused. It depends on how we choose to use it. And even if AI becomes more advanced, he feels that real human feelings will always be more powerful and important. On the work front, Pankaj Tripathi was last seen in Criminal Justice 4, which premiered on May 29 on JioHotstar. Up next, he'll appear in Anurag Basu's upcoming film Metro… In Dino. The film boasts a star-studded cast including Aditya Roy Kapur, Sara Ali Khan, Konkona Sen Sharma, Ali Fazal, Fatima Sana Shaikh, Anupam Kher, and Neena Gupta. Produced by T-Series Films and Anurag Basu Productions, Metro… In Dino is set to release in theatres on July 4, 2025. First Published:
Time of India
3 days ago
- Time of India
Evidence of CAR T-cell therapy against cancers presented at US conference
New Delhi: Studies have provided evidence of the effectiveness of CAR T-cell therapy against gastric and brain tumours. The papers, presented at the annual meeting of the American Society of Clinical Oncology [ASCO] 2025, held from May 30 to June 3 in Chicago, US, have also been published in journals, including The Lancet and Nature Medicine. Treating cancer using CAR T-cell therapy involves modifying genes in one's T-cells - a type of immune cell - to help fight cancer. In The Lancet paper, that revealed results of phase 2 clinical trials , 156 patients with advanced gastric or gastro-oesophageal junction cancer - and who were resistant to "at least two previous lines of treatment" - were randomly assigned to receive 'satri-cel' or an intervention of physician's choice. Satri-cel, or 'Satricabtagene autoleucel' - a CAR T-cell therapy -- showed "encouraging activity" in phase 1 clinical trials in treating patients with advanced gastric or gastro-oesophageal junction cancer, the team, including researchers from China's Peking University Cancer Hospital and Institute, said. A phase-1 trial primarily looks at establishing a new drug's safety and dose characteristics in about 20-100 healthy volunteers, while a 'phase-2' trial provides evidence of the effectiveness of the experimental drug in about 100-300 volunteers or participants. "In this multicentre, randomised, phase 2 study, satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC (treatment of physician's choice), along with a manageable safety profile in patients," the authors wrote. They added that it is the "first randomised controlled study of a CAR T-cell therapy in solid tumours". In the second study, published in the Nature Medicine journal, researchers from the University of Pennsylvania, US, said that CAR T-cell therapy "shows promise for slowing tumour growth in a notoriously aggressive and fast-growing brain cancer ". The phase-1 trial involved 18 patients with glioblastoma who received the treatment. "Tumour regression (becoming smaller) occurred in eight of 13 patients (62 per cent) with measurable disease," the authors wrote. In March, a CAR T-cell therapy, indigenously developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, showed a 73 per cent response rate in patients of leukaemia and lymphoma, who either relapsed following a period of remission or were resistant to treatment. The results of the phase 1 and 2 clinical trials are published in The Lancet Haematology journal. PTI
